Cytokinetics Inc
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: −8.52%.
Did CYTK Beat Earnings? Q4 2025 Results
Cytokinetics delivered a mixed fourth quarter for fiscal 2025, posting a sharp revenue beat alongside a wider-than-expected loss as the company absorbed the costs of transforming into a commercial-stage operation. Revenue came in at $17.75 million, a 4.9% increase year-over-year that more than doubled the $8.02 million consensus estimate, driven by milestone payments tied to regulatory approvals of MYQORZO under the Sanofi License Agreement. However, the earnings picture was less encouraging, with a net loss of $1.50 per share falling short of the $1.37 consensus by 9.67%, as G&A expenses surged to $91.72 million from $62.34 million a year earlier, reflecting aggressive U.S. sales force buildout ahead of the MYQORZO launch. Some analysts remain confident in the launch trajectory despite the cost pressure, pointing to early prescription activity as a constructive signal. Looking ahead, the company guided for combined GAAP R&D and SG&A of $830 million to $870 million in 2026, with key catalysts including ACACIA-HCM topline data in Q2 and a potential MAPLE-HCM FDA approval in Q4.
- FDA approval of MYQORZO in December 2025 enabling U.S. commercial launch
- $52.4 million technology transfer to Bayer in Q2 2025 drove full-year revenue increase
- $15 million in milestone revenues from Sanofi triggered by U.S. and China approvals in Q4
- Increased R&D expenses from advancing clinical trials and higher personnel costs
- G&A expense increase driven by U.S. sales force hiring and commercial readiness investments
“The fourth quarter of 2025 marked a defining moment for Cytokinetics with the FDA approval of MYQORZO and our transition into a commercial-stage company. With the U.S. launch of MYQORZO now underway and our first European launch planned in Germany in Q2, we're entering 2026 with strong momentum. Early prescribing activity and initial customer feedback reinforce that our differentiated label and REMS are resonating with HCPs and patients. We took measures in 2025 to fortify our balance sheet to support our commercial plans and continue with potential label-expanding opportunities in HCM and ongoing clinical trials in heart failure. We are well-positioned to deliver for patients, advance our pipeline, and create long-term value.”
Cytokinetics CEO, on the earnings call
Forward Guidance & Outlook
Cytokinetics provided 2026 financial guidance for GAAP combined R&D and SG&A expenses of $830 million to $870 million, including $120 million to $130 million in non-cash stock-based compensation. Key 2026 milestones include: ACACIA-HCM topline results in Q2 2026, MYQORZO launch in Germany in Q2 2026, potential FDA approval of the MAPLE-HCM sNDA in Q4 2026, completion of adolescent cohort enrollment in CEDAR-HCM by Q4 2026, potential Health Canada approval in H2 2026, continued enrollment in COMET-HF, and completion of AMBER-HFpEF Cohort 1 enrollment in Q1 2026 and Cohort 2 by year-end 2026.
CYTK YoY Financials
CYTK Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.